MXPA00010241A - Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. - Google Patents
Composicion farmaceutica que comprende el factor viii y liposomas neutrales..Info
- Publication number
- MXPA00010241A MXPA00010241A MXPA00010241A MXPA00010241A MXPA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- protein
- factor viii
- colloidal particles
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion farmaceutica para administracion parenteral que comprende una cantidad terapeuticamente efectiva de una proteina o polipeptido y particulas coloidales substancialmente neutrales. Las particulas comprenden aproximadamente 1-20 por ciento en mol de un derivado lipidico anfipatico con un polimero hidrofilico biocompatible el cual no porta substancialmente cargas netas. La proteina o polipeptido es capaz de enlazar externamente las particulas coloidales, o es capaz de enlazar polietilenglicol, y no se encapsula en las particulas coloidales. Una proteina preferida es el factor VIII, cuya vida media se prolonga y que se protege de los anticuerpos inhibidores de suero al inyectarse como un componente de la composicion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12422498 | 1998-04-27 | ||
PCT/IL1999/000217 WO1999055306A1 (en) | 1998-04-27 | 1999-04-23 | Pharmaceutical composition comprising factor viii and neutral liposomes |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00010241A true MXPA00010241A (es) | 2004-09-06 |
Family
ID=11071435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA00010241A MXPA00010241A (es) | 1998-04-27 | 1999-04-23 | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. |
Country Status (12)
Country | Link |
---|---|
US (2) | US6593294B1 (es) |
EP (1) | EP1079805B1 (es) |
JP (1) | JP4545928B2 (es) |
AT (1) | ATE283034T1 (es) |
AU (1) | AU747391B2 (es) |
BR (1) | BR9909978A (es) |
CA (1) | CA2329768C (es) |
DE (1) | DE69922189T2 (es) |
ES (1) | ES2233036T3 (es) |
MX (1) | MXPA00010241A (es) |
PT (1) | PT1079805E (es) |
WO (1) | WO1999055306A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8110218B2 (en) * | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
AU2002239607A1 (en) * | 2000-11-30 | 2002-06-11 | Baxter Healthcare Corporation | Ahf associated dispersion system and method for preparation |
US7625584B2 (en) * | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
CA2490959C (en) * | 2002-07-02 | 2013-04-16 | Board Of Regents, The University Of Texas System | Radiolabeled compounds and liposomes and their methods of making and using the same |
US7351688B2 (en) * | 2003-02-05 | 2008-04-01 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein formulations |
JP2006523683A (ja) * | 2003-04-15 | 2006-10-19 | オッパーバス・ホールディング・ビー・ブイ | タンパク質及び/またはポリペプチド及びコロイド粒子を含む医薬組成物 |
CA2534565C (en) * | 2003-08-05 | 2012-06-19 | The Research Foundation Of State University Of New York | Reconstitution medium for protein and peptide formulations |
WO2005079185A2 (en) * | 2003-09-02 | 2005-09-01 | Board Of Regents, The University Of Texas System | Neutral liposome-encapsulated compounds and methods of making and using thereof |
US7208174B2 (en) * | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
PL1713446T3 (pl) * | 2004-01-23 | 2011-05-31 | Camurus Ab | Nielamelarne trójskładnikowe kompozycje lipidów |
LT3130601T (lt) | 2004-11-12 | 2020-09-10 | Bayer Healthcare Llc | Į vietą nukreipta fviii modifikacija |
EP1874793A4 (en) * | 2005-04-15 | 2008-12-24 | Univ Texas | DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS |
CA2613705A1 (en) * | 2005-06-29 | 2007-01-04 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic pr0tein-lip1d complexes |
WO2007021822A2 (en) * | 2005-08-09 | 2007-02-22 | The Research Foundation Of State Of University Of New York At Buffalo | Compositions and methods of preparation of liposomal microparticulate il-12 |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
US7875288B2 (en) | 2006-03-30 | 2011-01-25 | The Research Foundation Of State University Of New York | Method for treating blood coagulation disorders |
AU2007235463B2 (en) * | 2006-03-30 | 2012-11-22 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
ES2521490T3 (es) | 2006-12-15 | 2014-11-12 | Baxter International Inc. | Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada. |
JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
CN102076855A (zh) | 2008-06-24 | 2011-05-25 | Csl百灵有限公司 | 具有延长的体内半衰期的因子viii,冯·维勒布兰德因子或它们的复合物 |
JP5681626B2 (ja) | 2008-07-14 | 2015-03-11 | ポリーペイド リミテッドPolypid Ltd. | 徐放性薬剤キャリア組成物 |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
WO2011007353A1 (en) | 2009-07-14 | 2011-01-20 | Polypid Ltd. | Sustained-release drug carrier composition |
EP2470287A4 (en) | 2009-08-28 | 2015-01-21 | Univ Columbia | SYSTEMS, METHODS AND DEVICES FOR PRODUCING GAS-FILLED MICROBUBBLES |
US20130028959A1 (en) | 2009-12-16 | 2013-01-31 | Massachusetts Institute Of Technology | Liposomes for Preventing the Spread of HIV |
US10010709B2 (en) | 2009-12-16 | 2018-07-03 | The Trustees Of Columbia University In The City Of New York | Composition for on-demand ultrasound-triggered drug delivery |
EP2525778B1 (en) | 2010-01-19 | 2018-08-01 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
US8637448B2 (en) | 2010-09-14 | 2014-01-28 | University Of Rochester | Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface |
DE102010043733A1 (de) | 2010-11-10 | 2012-05-10 | Oxprotect Gmbh | Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen |
PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
AU2015283822B2 (en) | 2014-07-02 | 2019-10-03 | CSL Behring Lengnau AG | Modified von willebrand factor |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
ES2774011T3 (es) | 2015-05-22 | 2020-07-16 | CSL Behring Lengnau AG | Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia |
EP3298036B1 (en) | 2015-05-22 | 2022-04-06 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
SG11201805494WA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
KR20180094114A (ko) | 2016-01-07 | 2018-08-22 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 돌연변이된 절단된 폰 빌레브란트 인자 |
WO2017220099A1 (en) | 2016-06-24 | 2017-12-28 | Statens Serum Institut | Adjuvants with modified drainage properties |
US11246832B2 (en) * | 2016-06-28 | 2022-02-15 | Verily Life Sciences Llc | Serial filtration to generate small cholesterol-containing liposomes |
TW201828974A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Csl貝林重組技能公司 | 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類 |
AU2017358861B2 (en) | 2016-11-11 | 2022-02-17 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7900459A (nl) | 1979-01-19 | 1980-07-22 | Hendrik Coenraad Hemker Prof D | Farmaceutisch preparaat en werkwijze ter bereiding daarvan. |
JPS56127307A (en) * | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical for oral administration |
US4348384A (en) | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
WO1991012021A2 (en) * | 1990-02-13 | 1991-08-22 | Oxford Virology Plc | Therapeutic agents, and intermediates for the synthesis thereof |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
-
1999
- 1999-04-23 PT PT99916022T patent/PT1079805E/pt unknown
- 1999-04-23 ES ES99916022T patent/ES2233036T3/es not_active Expired - Lifetime
- 1999-04-23 CA CA002329768A patent/CA2329768C/en not_active Expired - Fee Related
- 1999-04-23 DE DE69922189T patent/DE69922189T2/de not_active Expired - Lifetime
- 1999-04-23 AT AT99916022T patent/ATE283034T1/de active
- 1999-04-23 US US09/673,412 patent/US6593294B1/en not_active Expired - Lifetime
- 1999-04-23 JP JP2000545506A patent/JP4545928B2/ja not_active Expired - Fee Related
- 1999-04-23 AU AU34414/99A patent/AU747391B2/en not_active Ceased
- 1999-04-23 MX MXPA00010241A patent/MXPA00010241A/es active IP Right Grant
- 1999-04-23 WO PCT/IL1999/000217 patent/WO1999055306A1/en active IP Right Grant
- 1999-04-23 BR BR9909978-0A patent/BR9909978A/pt not_active Application Discontinuation
- 1999-04-23 EP EP99916022A patent/EP1079805B1/en not_active Expired - Lifetime
-
2002
- 2002-12-26 US US10/327,970 patent/US6930087B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1079805B1 (en) | 2004-11-24 |
BR9909978A (pt) | 2000-12-26 |
DE69922189T2 (de) | 2005-11-10 |
JP4545928B2 (ja) | 2010-09-15 |
CA2329768A1 (en) | 1999-11-04 |
US6930087B2 (en) | 2005-08-16 |
US20030134778A1 (en) | 2003-07-17 |
EP1079805A1 (en) | 2001-03-07 |
DE69922189D1 (de) | 2004-12-30 |
PT1079805E (pt) | 2005-03-31 |
CA2329768C (en) | 2008-06-10 |
WO1999055306A1 (en) | 1999-11-04 |
AU747391B2 (en) | 2002-05-16 |
ES2233036T3 (es) | 2005-06-01 |
JP2002512947A (ja) | 2002-05-08 |
AU3441499A (en) | 1999-11-16 |
ATE283034T1 (de) | 2004-12-15 |
US6593294B1 (en) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA00010241A (es) | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. | |
CA2155005A1 (en) | Pharmaceutical Compositions Containing Bactericidal Permeability Increasing Protein and a Surfactant | |
WO2002048183A3 (en) | Compositions of peptide crystals | |
DE69312947T2 (de) | Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe | |
EP0783299A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES | |
AU7678196A (en) | Methods and compositions for the delivery of monomeric proteins | |
EP0993831A3 (en) | Compounds and compositions for delivering active agents | |
EP1273304A3 (en) | Use of interleukin-15 | |
EP1077070A3 (en) | Oral drug delivery compositions | |
FI962154A0 (fi) | Koostumus terapeuttisten tuotteiden in vivo valmistusta varten | |
IS5087A (is) | Stöðugar interferónlyfjablöndur á vökvaformi | |
AU2272097A (en) | Drug delivery compositions suitable for intravenous injection | |
WO1997010851A3 (en) | Nucleic acid delivery vehicle | |
UA65561A (en) | Therapeutic agent for lymphatic tumors | |
EP0422125A4 (en) | Platelet blocking peptides | |
AU7683296A (en) | Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them | |
AU2975899A (en) | Colonic delivery of protein or peptide compositions | |
WO1994016723A3 (en) | Wound healing composition | |
WO2001083783A3 (en) | In vivo loading of mhc | |
MXPA05010926A (es) | Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales. | |
MX9705082A (es) | Composiciones para el suministro de antigenos. | |
WO2000071573A3 (en) | Immunogenic peptides derived from mage and the use thereof | |
WO2003087329A3 (en) | Targeted cytocidal virionoids for antiangiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights | ||
PD | Change of proprietorship |
Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.* |
|
PD | Change of proprietorship |
Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.* |